📊 AKTS Key Takeaways
Is Aktis Oncology, Inc. (AKTS) a Good Investment?
Unable to perform meaningful fundamental analysis due to absence of reported financial data across all key metrics. Company shows recent insider activity (7 Form 4 filings in 90 days) suggesting active management engagement, but lack of revenue, profitability, and balance sheet transparency prevents any credible assessment of financial health or investment merit.
Aktis Oncology shows the typical weak profitability profile of an early-stage biotech: minimal collaboration revenue, no commercial revenue base, and widening operating losses as R&D spending scales. The main fundamental offset is balance-sheet strength, with roughly $246 million of cash, cash equivalents, and marketable securities at September 30, 2025 and substantial IPO proceeds that appear to extend runway into 2029, giving the company time to advance its pipeline without near-term balance-sheet stress.
Aktis Oncology, Inc. Key Strengths (AKTS)
- Recent insider activity indicates engaged management team
- Biopharmaceutical sector allows for potential pipeline value creation
- Listed on Nasdaq suggests prior compliance with exchange standards
- Strong liquidity position with large cash and marketable securities balance, further boosted by January 2026 IPO proceeds
- Limited financial leverage, with liabilities driven mainly by deferred revenue and lease obligations rather than debt
- Some non-dilutive collaboration revenue and deferred revenue provide external validation and modest funding support
AKTS Stock Risks: Aktis Oncology, Inc. Investment Risks
- Complete absence of financial reporting data across income statement, balance sheet, and cash flow metrics
- No revenue generation apparent, typical of pre-commercialization biotech
- Inability to assess liquidity, solvency, or operational viability without financial statements
- Profitability is poor and deteriorating, with operating loss and net loss increasing as R&D investment expands
- Revenue quality is weak because it is small, collaboration-based, and not supported by commercial product sales
- The company will likely require additional capital before any product reaches regulatory approval or commercialization
Key Metrics to Watch
- Revenue and gross profit recognition upon any product commercialization
- Cash position and runway given typical biotech cash burn
- Operating cash flow trends and path to profitability or strategic milestone achievement
- Quarterly cash burn relative to total cash, cash equivalents, and marketable securities
- R&D expense growth versus pipeline progress and collaboration revenue/deferred revenue trends
Aktis Oncology, Inc. (AKTS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AKTS Profit Margin, ROE & Profitability Analysis
AKTS vs Healthcare Sector: How Aktis Oncology, Inc. Compares
How Aktis Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aktis Oncology, Inc. Stock Overvalued? AKTS Valuation Analysis 2026
Based on fundamental analysis, Aktis Oncology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aktis Oncology, Inc. Balance Sheet: AKTS Debt, Cash & Liquidity
AKTS Revenue Growth, EPS Growth & YoY Performance
AKTS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.4M | -$15.0M | $-0.38 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AKTS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aktis Oncology, Inc. (CIK: 0002035832)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AKTS
What is the AI rating for AKTS?
Aktis Oncology, Inc. (AKTS) has a Combined AI Grade of B from Claude (B) and ChatGPT (B) with 42% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AKTS's key strengths?
Claude: Recent insider activity indicates engaged management team. Biopharmaceutical sector allows for potential pipeline value creation. ChatGPT: Strong liquidity position with large cash and marketable securities balance, further boosted by January 2026 IPO proceeds. Limited financial leverage, with liabilities driven mainly by deferred revenue and lease obligations rather than debt.
What are the risks of investing in AKTS?
Claude: Complete absence of financial reporting data across income statement, balance sheet, and cash flow metrics. No revenue generation apparent, typical of pre-commercialization biotech. ChatGPT: Profitability is poor and deteriorating, with operating loss and net loss increasing as R&D investment expands. Revenue quality is weak because it is small, collaboration-based, and not supported by commercial product sales.
What is AKTS's revenue and growth?
Aktis Oncology, Inc. reported revenue of N/A.
Does AKTS pay dividends?
Aktis Oncology, Inc. does not currently pay dividends.
Where can I find AKTS SEC filings?
Official SEC filings for Aktis Oncology, Inc. (CIK: 0002035832) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AKTS's EPS?
Aktis Oncology, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AKTS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aktis Oncology, Inc. has a B grade with 42% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AKTS stock overvalued or undervalued?
Valuation metrics for AKTS: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AKTS's AI grade for 2026?
Our dual AI analysis gives Aktis Oncology, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AKTS's free cash flow?
Aktis Oncology, Inc.'s operating cash flow is N/A, with capital expenditures of N/A.
How does AKTS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).